<DOC>
	<DOCNO>NCT02534077</DOCNO>
	<brief_summary>To provide mechanism critically ill infant parenteral nutrition ( PN ) associate cholestasis receive Omegaven compassionate use situation satisfactory alternative treatment .</brief_summary>
	<brief_title>Intravenous Fat Emulsion Comprised Fish Oil Treatment Parenteral Nutrition Induced Liver Injury Infants</brief_title>
	<detailed_description />
	<mesh_term>Cholestasis</mesh_term>
	<mesh_term>Fat Emulsions , Intravenous</mesh_term>
	<criteria>1 . Critically ill infant either know anatomic short gut ( great 50 % bowel remove ) know severe dysmotility gut reflect nonfunctional gut similar anatomic short gut offer Omegaven® direct bilirubin reach 2 mg/dL . Infants meet criterion anatomic dysfunctional short gut allow receive Omegaven® direct bilirubin reach 4 mg/dL . The qualify measurement 2 mg/dL 4 mg/dL direct bilirubin must consecutive obtain least 24 hour apart . 2 . Be expect require intravenous nutrition least additional 28 day 3 . Patient must document failure ineligibility follow therapy prevent progression PNALD : Reduction Intralipid® 1 g/kg/day Limiting trace mineral include copper manganese Initiation use Ursodiol Cycling parenteral nutrition Advancement enteral feeding 4 . Parental inform consent must sign . 1 . Have congenitally lethal condition ( e.g . Trisomy 13 ) . 2 . Have clinically severe bleed able manage routine measure . 3 . Have evidence viral hepatitis primary liver disease primary etiology cholestasis . 4 . Have health problem survival extremely unlikely even infant 's cholestasis improve . 5 . Has culture positive sepsis</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>2 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>omegaven</keyword>
	<keyword>cholestasis</keyword>
	<keyword>parenteral nutrition associate liver disease</keyword>
</DOC>